RDHL — RedHill Biopharma Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1553846 ·
Last close
$0.35
Market Cap
$2.13M
52W High
$1.60
52W Low
$0.35
ADV30
623,685
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 26,274,000 5,159,000 27,353,000
Dec 2025 — — — — 25,345,000 3,971,000 21,077,000
Jun 2025 — — — — 18,375,000 2,866,000 22,787,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-419,164,000
Inventory
$0
Receivables
$3,415,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$286,000
EBITDA
$-7,793,000
Free Cash Flow
$-2,176,000
Enterprise Value
$383,041
Total Cash
$3,971,000
Total Debt
$1,070,000
Shares Out
6,080,920
Trailing EPS
$0.00
Book Value
$0.84
ROE
—
ROA
-22.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 286,000 -7,909,000 -429,000 25,345,000 21,077,000 4,268,000 -9,651,000
Dec 2024 0 -6,475,000 -8,268,000 18,043,000 22,726,000 -4,683,000 -9,369,000
Dec 2023 0 -9,547,000 23,916,000 23,047,000 20,978,000 2,069,000 -35,820,000
Dec 2022 61,800,000 -42,844,000 -71,669,000 158,870,000 207,270,000 -48,400,000 -29,185,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.03

Peers — same industry

TickerNameMarket CapLastDaily %
SBFM Sunshine Biopharma Inc. $2.09M $2.54 —
CVSI CV Sciences, Inc. $2.17M $0.01 —
BDRX Biodexa Pharmaceuticals Plc $2.20M $2.14 —
CASIF CASI Pharmaceuticals, Inc. $2.06M $0.10 —
REVB REVELATION BIOSCIENCES, INC. $2.21M $3.88 —

News headlines (Yahoo Finance, 1h cache)

RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
2026-11-17 14:18 · Yahoo
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
2026-10-19 12:00 · Yahoo
RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
2026-09-10 16:06 · Yahoo
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
2026-08-31 11:00 · Yahoo
RedHill Biopharma Announces Up To $19.4 Million Private Placement
2026-06-18 12:00 · Yahoo
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
2026-06-02 12:00 · Yahoo
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
2026-06-08 11:00 · Yahoo
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
2026-11-02 12:00 · Yahoo
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet
2026-10-01 19:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.